A Multi-Institution Study of TGFβ Imprinted, Ex Vivo Expanded Universal Donor NK Cell Infusions as Adoptive Immunotherapy in Combination With Gemcitabine and Docetaxel in Patients With Relapsed or Refractory Pediatric Bone and Soft Tissue
Clinical trial NCT05634369 · RECRUITING
Trial details
- NCT number
- NCT05634369
- Sponsor
- Nationwide Children's Hospital
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-11-14
- Primary completion
- 2026-12-01
- Enrollment
- 50
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.